PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
187.54%
Cash & equivalents growing 187.54% while AVXL's declined -3.87%. Peter Lynch would see this as a sign of superior liquidity management.
No Data
No Data available this quarter, please select a different quarter.
187.23%
Below half of AVXL's -3.87%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
168.93%
Below half of AVXL's -4.12%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-20.60%
≥ 1.5x AVXL's -11.08%. David Dodd sees more aggressive capex. Confirm it's not overspending.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-16.19%
1.25-1.5x AVXL's -11.08%. Bruce Berkowitz checks if expansions surpass competitor's pace but remain justified.
No Data
No Data available this quarter, please select a different quarter.
164.96%
Below half of AVXL's -4.12%. Michael Burry sees a potential red flag for stagnation or capital shortage.
-45.35%
Less than half of AVXL's 5.18%. David Dodd sees a more disciplined AP approach or lower volume.
-33.08%
50-75% of AVXL's -48.81%. Bruce Berkowitz notes the firm is less reliant on near-term borrowing than competitor.
No Data
No Data available this quarter, please select a different quarter.
43.64%
Below half of AVXL's -5.18%. Michael Burry suspects a big gap in pre-sales traction.
-68.51%
Less than half of AVXL's 26.57%. David Dodd sees fewer expansions in other current obligations.
-61.96%
Above 1.5x AVXL's -1.60%. Michael Burry sees a red flag for liquidity risk vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-61.96%
Above 1.5x AVXL's -8.15%. Michael Burry sees a potential leverage warning sign.
19.13%
1.1-1.25x AVXL's 16.11%. Bill Ackman questions if the firm is issuing more stock than competitor.
-3.37%
≥ 1.5x AVXL's -1.50%. David Dodd sees higher yoy retained profits than competitor.
-26.34%
Similar yoy to AVXL's -32.42%. Walter Schloss sees parallel comprehensive income changes.
No Data
No Data available this quarter, please select a different quarter.
955.36%
≥ 1.5x AVXL's 145.62%. David Dodd sees stronger capital base growth than competitor.
164.96%
Below half AVXL's -4.12%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-33.08%
Above 1.5x AVXL's -11.07%. Michael Burry sees a major jump. Investigate leverage rationale.
-197.28%
Above 1.5x AVXL's -27.63%. Michael Burry sees a major gap in net debt growth. Check coverage and liquidity.